This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the potential of barzolvolimab for patients with Chronic Spontaneous Urticaria (CSU) and the 52 week results from the Phase 2 study of barzolvolimab in CSU presented at the EADV Congress 2024.
Ticker(s): CLDXWho's the expert?
Gregory Toci MD
- Allergist and Immunologist
- Treats about 100 patients with CSU a year across all age group
- familiar with the 52 week results from the Phase 2 study of barzolvolimab in CSU presented at the EADV Congress 2024
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
